Investor/Media Center

print page

Press Releases

 


Displaying releases: 1-40 | 41-80 | 81-120 | 121-160 | 161-200 | 201-218


Feb-10-2016 Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2016 Results
Feb-08-2016 Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction
Feb-04-2016 Palatin Technologies to present at the BIO CEO & Investor Conference
Dec-10-2015 Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction
Nov-12-2015 Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2016 Results
Nov-10-2015 Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2016 Results
Sep-28-2015 Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting
Sep-21-2015 Palatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction
Sep-21-2015 Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results
Sep-16-2015 Palatin Technologies, Inc. To Report Fourth Quarter Fiscal Year End 2015 Results
Aug-18-2015 Palatin Technologies Supports FDAs Approval of the First-Ever Treatment for Female Sexual Dysfunction
Jul-06-2015 Palatin Technologies Completes $30 Million Financing
May-13-2015 Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2015 Results
May-08-2015 Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2015 Results
Mar-06-2015 Palatin Technologies to Present at the 27th Annual ROTH Conference
Feb-20-2015 Palatin Launches reconnectstudy.com in Support of Bremelanotide Phase 3 Program for Female Sexual Dysfunction
Feb-13-2015 Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on February 13, 2015
Feb-09-2015 Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2015 Results Teleconference and Webcast to be held on February 13, 2015
Feb-06-2015 PALATIN TECHNOLOGIES TO PRESENT AT THE BIO CEO & INVESTOR CONFERENCE
Dec-29-2014 Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
Dec-24-2014 Palatin Completes $20 Million Equity and $10 Million Debt Financings
Nov-18-2014 Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014
Nov-13-2014 Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2015 Results
Oct-08-2014 Palatin Technologies To Present At The 13th Annual Bio Investor Forum
Sep-09-2014 Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Results
Sep-04-2014 Palatin Technologies, Inc. To Report Fourth Quarter and Fiscal Year 2014 Results Teleconference and Webcast to be held on September 9, 2014
Sep-03-2014 Palatin Technologies Licenses Bremelanotide in Europe and Other Selected Countries to Richter
Jul-09-2014 Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
Jun-27-2014 Palatin Technologies to Join Russell Microcap Index
Jun-10-2014 Palatin Technologies Announces Notification of Patent Allowance On Next Generation Melanocortin Receptor-Specific Peptides
May-13-2014 Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on May 13, 2014
May-09-2014 Palatin Technologies, Inc. To Report Third Quarter Fiscal Year 2014 Results Teleconference and Webcast to be held on May 13, 2014
May-06-2014 Palatin Technologies Presents at the American Psychiatric Association (APA)
May-01-2014 Palatin Technologies Announces Option Exercise by Specialty Pharmaceutical Company to License Bremelanotide in Europe
Apr-29-2014 Palatin Technologies Presents at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG)
Mar-31-2014 Palatin Technologies Announces Option Extension for License to Bremelanotide in Europe
Mar-06-2014 Palatin Technologies to present at the 26th Annual ROTH Conference
Feb-24-2014 Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder
Feb-18-2014 Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on February 18, 2014
Feb-13-2014 Palatin Technologies, Inc. To Report Second Quarter Fiscal Year 2014 Results Teleconference and Webcast to be held on February 18, 2014